LY2140023 (LY404039)
Jump to navigation
Jump to search
Indications
- experimental drug used to treat schizophrenia
Pharmacokinetics
- prodrug hydrolyzed to LY404039
Mechanism of action
- LY404039 is a metabotropic glutamate receptor agonist specific for mGluR2 & mGluR3
More general terms
References
- ↑ Patil ST et al Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 2007 Sep; 13:1102. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17767166
Weinberger DR. Schizophrenia drug says goodbye to dopamine. Nat Med 2007 Sep; 13:1018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17828217